

Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

Mentice (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that a global healthcare technology leader and existing customer of Mentice has signed an agreement to acquire Mentice VIST® development services for USD 795,000.

“This order represents further support for improved patient safety from one of our largest global customers where investment in advanced training solutions are a strategic part of implementation and adoption of new medical device solutions”, states Göran Malmberg, CEO of Mentice AB.

The order will be recognized for the Medical Device Industry business area during the first quarter of 2024, and most of the revenues will be recognized in 2024.

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-02 08:30 CEST.

Attachments

[Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company](#)